Breast Cancer Clinical Trial

Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients

Summary

The purpose of this study is to find out the effects of acupuncture on reducing nerve damage.

Acupuncture is a medical technique of inserting very thin needles into the "energy points" on the body with the aim to restore health and well-being. It has been used widely to treat pain, such as lower back pain and joint pain. In this study the investigators will assess if acupuncture can be used to ease the pain, tingling and numbness that may be caused by chemotherapy and improve quality of life during chemotherapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Screening Phase:

Age 21 or older.
Histologically proven stage I-III carcinoma of the breast.
Plan to receive adjuvant or neoadjuvant chemotherapy that includes weekly paclitaxel.
Eastern Cooperative Oncology Group performance status 0-2 (see Appendix B).
The patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.
Proficiency in English with the ability to speak and read English.

Exclusion Criteria:

Known metastatic (stage IV) breast cancer involvement.
Pre-existing peripheral neuropathy within 28 days of screening consent
Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine.

Intervention Phase:

Age 21 or older.
Histologically proven stage I-III carcinoma of the breast.
Receiving adjuvant or neoadjuvant chemotherapy that includes a taxane.
Eastern Cooperative Oncology Group performance status 0-2
The patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.
Proficiency in English with the ability to speak and read English
While on neurotoxic chemotherapy, has developed NCI-CTC grade 2 CIPN

Exclusion Criteria:

Known metastatic (stage IV) breast cancer involvement.
Pre-existing peripheral neuropathy within 28 days of screening consent.
Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine.

Study is for people with:

Breast Cancer

Estimated Enrollment:

28

Study ID:

NCT02364726

Recruitment Status:

Active, not recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Memorial Sloan Kettering Westchester
Harrison New York, 10604, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

28

Study ID:

NCT02364726

Recruitment Status:

Active, not recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider